The endothelin type a receptor as a potential therapeutic target in preeclampsia

International Journal of Molecular Sciences

Volumn 18, Issue 3, 2017, Pages

  Bakrania, Bhavisha ^a   Duncan, Jeremy ^a   Warrington, Junie P ^a   Granger, Joey P ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Blood pressure; Cardiovascular; Endothelin; Endothelium; Hypertension; Placenta; Preeclampsia; Pregnancy; Vascular smooth muscle

Indexed keywords

ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; APELIN RECEPTOR; CD135 ANTIGEN; ENDOGLIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; MATRIX METALLOPROTEINASE; PLACENTAL GROWTH FACTOR; PREPROENDOTHELIN; PROTEINASE ACTIVATED RECEPTOR 1; SOLUBLE FMS LIKE TYROSINE KINASE 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST;

DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; KIDNEY FAILURE; LUNG EDEMA; MEAN ARTERIAL PRESSURE; MRNA EXPRESSION ASSAY; NONHUMAN; OBESITY; OXIDATIVE STRESS; PREECLAMPSIA; PREGNANT WOMAN; PROTEIN EXPRESSION; PROTEINURIA; REPERFUSION INJURY; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; VASCULAR SMOOTH MUSCLE; VISUAL DISORDER; ANIMAL; DISEASE MODEL; DRUG EFFECTS; ENDOTHELIUM; FEMALE; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PRE-ECLAMPSIA; PREGNANCY; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; ENDOTHELIN A RECEPTOR ANTAGONISTS; ENDOTHELINS; ENDOTHELIUM; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; PRE-ECLAMPSIA; PREGNANCY; RECEPTOR, ENDOTHELIN A; SIGNAL TRANSDUCTION;

EID: 85014324666     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18030522     Document Type: Review

References (41)

1. Roberts, J.M.; Taylor, R.N.; Goldfien, A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am. J. Hypertens. 1991, 4, 700–708. [CrossRef] [PubMed]
2. Granger, J.P.; Alexander, B.T.; Llinas, M.T.; Bennett, W.A.; Khalil, R.A. Pathophysiology of preeclampsia: Linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation 2002, 9, 147–160. [CrossRef] [PubMed]
3. Palei, A.C.; Spradley, F.T.; Warrington, J.P.; George, E.M.; Granger, J.P. Pathophysiology of hypertension in pre-eclampsia: A lesson in integrative physiology. Acta Physiol. 2013, 208, 224–233. [CrossRef] [PubMed]
4. Brosens, I.A.; Robertson, W.B.; Dixon, H.G. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet. Gynecol. Annu. 1972, 1, 177–191. [CrossRef] [PubMed]
5. Gilbert, J.S.; Ryan, M.J.; LaMarca, B.B.; Sedeek, M.; Murphy, S.R.; Granger, J.P. Pathophysiology of hypertension during preeclampsia: Linking placental ischemia with endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2008, 294, 541–550. [CrossRef] [PubMed]
6. LaMarca, B.D.; Gilbert, J.; Granger, J.P. Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension 2008, 51, 982–988. [CrossRef] [PubMed]
7. LaMarca, B.D.; Ryan, M.J.; Gilbert, J.S.; Murphy, S.R.; Granger, J.P. Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Curr. Hypertens. Rep. 2007, 9, 480–485. [CrossRef] [PubMed]
8. Murphy, S.R.; LaMarca, B.B.; Cockrell, K.; Granger, J.P. Role of endothelin in mediating soluble Fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension 2010, 55, 394–398. [CrossRef] [PubMed]
9. George, E.M.; Granger, J.P. Endothelin: Key mediator of hypertension in preeclampsia. Am. J. Hypertens. 2011, 24, 964–969. [CrossRef] [PubMed]
10. George, E.M.; Granger, J.P. Linking placental ischemia and hypertension in preeclampsia: Role of endothelin 1. Hypertension 2012, 60, 507–511. [CrossRef] [PubMed]
11. George, E.M.; Palei, A.C.; Granger, J.P. Endothelin as a final common pathway in the pathophysiology of preeclampsia: Therapeutic implications. Curr. Opin. Nephrol. Hypertens. 2012, 21, 157–162. [CrossRef] [PubMed]
12. Granger, J.P.; Abram, S.; Stec, D.; Chandler, D.; LaMarca, B. Endothelin, the kidney, and hypertension. Curr. Hypertens. Rep. 2006, 8, 298–303. [CrossRef] [PubMed]
13. Benigni, A.; Orisio, S.; Gaspari, F.; Frusca, T.; Amuso, G.; Remuzzi, G. Evidence against a pathogenetic role for endothelin in pre-eclampsia. Br. J. Obstet. Gynaecol. 1992, 99, 798–802. [CrossRef] [PubMed]
14. Mastrogiannis, D.S.; O’Brien, W.F.; Krammer, J.; Benoit, R. Potential role of endothelin-1 in normal and hypertensive pregnancies. Am. J. Obstet. Gynecol. 1991, 165, 1711–1716. [CrossRef]
15. Taylor, R.N.; Varma, M.; Teng, N.N.; Roberts, J.M. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J. Clin. Endocrinol. Metab. 1990, 71, 1675–1677. [CrossRef] [PubMed]
16. Verdonk, K.; Saleh, L.; Lankhorst, S.; Smilde, J.E.; van Ingen, M.M.; Garrelds, I.M.; Friesema, E.C.; Russcher, H.; van den Meiracker, A.H.; Visser, W.; et al. Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression. Hypertension 2015, 65, 1316–1323. [CrossRef] [PubMed]
17. Aggarwal, P.K.; Chandel, N.; Jain, V.; Jha, V. The relationship between circulating endothelin-1, soluble Fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. J. Hum. Hypertens. 2012, 26, 236–241. [CrossRef] [PubMed]
18. Alexander, B.T.; Rinewalt, A.N.; Cockrell, K.L.; Massey, M.B.; Bennett, W.A.; Granger, J.P. Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension 2001, 37, 485–489. [CrossRef] [PubMed]
19. LaMarca, B.; Parrish, M.; Ray, L.F.; Murphy, S.R.; Roberts, L.; Glover, P.; Wallukat, G.; Wenzel, K.; Cockrell, K.; Martin, J.N., Jr.; et al. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1–AA) in pregnant rats: Role of endothelin-1. Hypertension 2009, 54, 905–909. [CrossRef] [PubMed]
20. Abdalvand, A.; Morton, J.S.; Bourque, S.L.; Quon, A.L.; Davidge, S.T. Matrix metalloproteinase enhances big-endothelin-1 constriction in mesenteric vessels of pregnant rats with reduced uterine blood flow. Hypertension 2013, 61, 488–493. [CrossRef] [PubMed]
21. Nugent, W.H.; Mishra, N.; Strauss, J.F., 3rd; Walsh, S.W. Matrix metalloproteinase 1 causes vasoconstriction and enhances vessel reactivity to angiotensin ii via protease-Activated receptor 1. Reprod. Sci. 2016, 23, 542–548. [CrossRef] [PubMed]
22. Alexander, B.T.; Llinas, M.T.; Kruckeberg, W.C.; Granger, J.P. L-arginine attenuates hypertension in pregnant rats with reduced uterine perfusion pressure. Hypertension 2004, 43, 832–836. [CrossRef] [PubMed]
23. George, E.; Granger, J.P.; Roberts, J.M. Chapter 10-animal models for investigating pathophysiological mechanisms of preeclampsia. In Chesley's Hypertensive Disorders in Pregnancy, 4th ed.; Taylor, R., Roberts, J.M., Cunningham, F.G., Lindheimer, M.D., Eds.; Academic Press: Tokyo, Japan, 2014; pp. 209–220.
24. Granger, J.P.; LaMarca, B.B.; Cockrell, K.; Sedeek, M.; Balzi, C.; Chandler, D.; Bennett, W. Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. Methods Mol. Med. 2006, 122, 383–392. [PubMed]
25. Alexander, B.T.; Kassab, S.E.; Miller, M.T.; Abram, S.R.; Reckelhoff, J.F.; Bennett, W.A.; Granger, J.P. Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. Hypertension 2001, 37, 1191–1195. [CrossRef] [PubMed]
26. Crews, J.K.; Herrington, J.N.; Granger, J.P.; Khalil, R.A. Decreased endothelium-dependent vascular relaxation during reduction of uterine perfusion pressure in pregnant rat. Hypertension 2000, 35, 367–372. [CrossRef] [PubMed]
27. Roberts, L.; LaMarca, B.B.; Fournier, L.; Bain, J.; Cockrell, K.; Granger, J.P. Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion. Hypertension 2006, 47, 615–618. [CrossRef] [PubMed]
28. Tam Tam, K.B.; George, E.; Cockrell, K.; Arany, M.; Speed, J.; Martin, J.N., Jr.; Lamarca, B.; Granger, J.P. Endothelin type a receptor antagonist attenuates placental ischemia-induced hypertension and uterine vascular resistance. Am. J. Obstet. Gynecol. 2011, 204, 330.e1–330.e4. [CrossRef] [PubMed]
29. Zhou, J.; Xiao, D.; Hu, Y.; Wang, Z.; Paradis, A.; Mata-Greenwood, E.; Zhang, L. Gestational hypoxia induces preeclampsia-like symptoms via heightened endothelin-1 signaling in pregnant rats. Hypertension 2013, 62, 599–607. [CrossRef] [PubMed]
30. Kappers, M.H.; Smedts, F.M.; Horn, T.; van Esch, J.H.; Sleijfer, S.; Leijten, F.; Wesseling, S.; Strevens, H.; Jan Danser, A.H.; van den Meiracker, A.H. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension 2011, 58, 295–302. [CrossRef] [PubMed]
31. Kappers, M.H.; de Beer, V.J.; Zhou, Z.; Danser, A.H.; Sleijfer, S.; Duncker, D.J.; van den Meiracker, A.H.; Merkus, D. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 2012, 59, 151–157. [CrossRef] [PubMed]
32. Redman, C.W.; Sargent, I.L. Immunology of pre-eclampsia. Am. J. Reprod. Immunol. 2010, 63, 534–543. [CrossRef] [PubMed]
33. Redman, C.W.; Tannetta, D.S.; Dragovic, R.A.; Gardiner, C.; Southcombe, J.H.; Collett, G.P.; Sargent, I.L. Review: Does size matter? Placental debris and the pathophysiology of pre-eclampsia. Placenta 2012, 33, 48–54. [CrossRef] [PubMed]
34. LaMarca, B.B.; Cockrell, K.; Sullivan, E.; Bennett, W.; Granger, J.P. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension 2005, 46, 82–86. [CrossRef] [PubMed]
35. Wang, W.; Parchim, N.F.; Iriyama, T.; Luo, R.; Zhao, C.; Liu, C.; Irani, R.A.; Zhang, W.; Ning, C.; Zhang, Y.; et al. Excess light contributes to placental impairment, increased secretion of vasoactive factors, hypertension, and proteinuria in preeclampsia. Hypertension 2014, 63, 595–606. [CrossRef] [PubMed]
36. Zhou, C.C.; Irani, R.A.; Dai, Y.; Blackwell, S.C.; Hicks, M.J.; Ramin, S.M.; Kellems, R.E.; Xia, Y. Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia. J. Immunol. 2011, 186, 6024–6034. [CrossRef] [PubMed]
37. Mazzuca, M.Q.; Li, W.; Reslan, O.M.; Yu, P.; Mata, K.M.; Khalil, R.A. Downregulation of microvascular endothelial type B endothelin receptor is a central vascular mechanism in hypertensive pregnancy. Hypertension 2014, 64, 632–643. [CrossRef] [PubMed]
38. Clouthier, D.E.; Hosoda, K.; Richardson, J.A.; Williams, S.C.; Yanagisawa, H.; Kuwaki, T.; Kumada, M.; Hammer, R.E.; Yanagisawa, M. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development 1998, 125, 813–824. [PubMed]
39. Kingman, M.; Ruggiero, R.; Torres, F. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin. Pharmacother. 2009, 10, 1847–1858. [CrossRef] [PubMed]
40. A receptors. Life Sci. 2003, 74, 405–409. [CrossRef] [PubMed]
41. Thaete, L.G.; Khan, S.; Synowiec, S.; Dayton, B.D.; Bauch, J.; Neerhof, M.G. Endothelin receptor antagonist has limited access to the fetal compartment during chronic maternal administration late in pregnancy. Life Sci. 2012, 91, 583–586. [CrossRef] [PubMed]